Hydrogen Therapy Boosts Immune System to Fight Cancer in Mice
- Authors
- Xueqi Liang, Zhen Liu, Nan Wang, Xiao-Kun Ouyang, Junhong Ling
- Journal
- Advanced Healthcare Materials
- Year
- 2026
- DOI
- 10.1002/adhm.202505332
- Study Type
- Mouse
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- China
- Health Condition
- Cancer
- Body System
- Immune System
TL;DR
A calcium-based nanoparticle that releases hydrogen enhanced anti-tumor immune responses and slowed tumor growth by improving the tumor immune environment.
Key Finding
In mouse tumors, a nanoparticle releasing both calcium and hydrogen gas together reduced tumor growth more effectively than either approach alone by triggering immune cell activation and reducing tumor-protective inflammation.
Summary
Researchers developed a nanoparticle (tiny engineered particle) called Ca@CMPN that releases calcium and hydrogen gas inside tumor cells. When tested in mice, this nanoparticle caused cancer cells to die in a way that triggered the immune system to attack remaining tumors, while hydrogen gas reduced harmful inflammation in the tumor environment. The combination of calcium overload and hydrogen appeared to work together to slow tumor growth and activate immune cells.
Practical Takeaway
This is early-stage laboratory research in mice only, not human studies. While the results suggest hydrogen gas may have immune-supporting properties when combined with other therapies, this nanoparticle platform is not available as a consumer product and much more research is needed before any conclusions about hydrogen water for cancer could be drawn.
Abstract
Immunogenic cell death (ICD) induced by calcium overload holds great promise for reversing the immunosuppressive tumor microenvironment (TME) and improving cancer immunotherapy. However, achieving sustained calcium dysregulation remains a major challenge. Herein, we report a novel nanoplatform, termed Ca@CMPN, which co-delivers calcium hydride and curcumin using a mesoporous polydopamine carrier for synergistic ion-interference and gas immunotherapy. Upon encountering the acidic TME, Ca@CMPN disintegrates to release Ca2+, initiating intracellular calcium overload, and concurrently generates hydrogen gas (H2). Crucially, the co-released curcumin acts from within the cell, amplifying the calcium overload by disrupting organellar calcium homeostasis, thereby ensuring robust ICD. Meanwhile, H2 serves as a potent immunoadjuvant to alleviate oxidative stress and remodel the immunosuppressive TME. Both in vitro and in vivo studies demonstrate that Ca@CMPN effectively inhibits tumor growth and reprograms the TME, as evidenced by enhanced dendritic cell maturation, activation of cytotoxic T cells, and elevated levels of pro-inflammatory cytokines (interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α)). This work presents a paradigm-shifting strategy that synergizes ion-interference therapy with hydrogen immunotherapy, offering a powerful nanoplatform to unlock the full potential of cancer immunotherapy.